サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：閉塞性睡眠時無呼吸症候群 (OSA) - KOLの考察、競合インテリジェンス、市場アナリティクス・予測 (2030年まで)
市場調査レポート
商品コード
997049

閉塞性睡眠時無呼吸症候群 (OSA) - KOLの考察、競合インテリジェンス、市場アナリティクス・予測 (2030年まで)

Obstructive Sleep Apnea (OSA) | Primary Research (KOL's Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
出版日: | 発行: Mellalta Meets LLP | ページ情報: 英文 152 Pages | 納期: 即納可能 即納可能とは
AI翻訳ツール 提供対象
ご購入後の翻訳ツール提供について

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=129.43円
閉塞性睡眠時無呼吸症候群 (OSA) - KOLの考察、競合インテリジェンス、市場アナリティクス・予測 (2030年まで)
出版日: 2021年02月28日
発行: Mellalta Meets LLP
ページ情報: 英文 152 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界保健機関（WHO）が実施した調査によると、閉塞性睡眠時無呼吸症候群 (OSA) の世界の有病者数は約1億人です。米国だけでも、OSAの患者数は約4,200万人です。米国では、成人の5人に1人が軽度のOSAで、15人に1人が中程度から重度のOSAです。OSAの症例数は、睡眠関連障害の有病者数の増加により、予測期間中に増加すると予想されています。

閉塞性睡眠時無呼吸症候群 (OSA) 有病者数

閉塞性睡眠時無呼吸症候群 (OSA) 市場規模：国別

当レポートでは、閉塞性睡眠時無呼吸症候群 (OSA) 市場について調査分析し、市場動向、G7の症例数、市場機会、市場予測、競合分析などについて、体系的な情報を提供しています。

目次

閉塞性睡眠時無呼吸症候群 (OSA) の背景

  • 閉塞性睡眠時無呼吸症候群 (OSA) の定義
  • 症状
  • 危険因子
  • 診断

疫学の推定と予測

疫学の調査手法と使用したデータソース

  • 米国における閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • 米国における重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • 米国における閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数
  • ドイツにおける閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • ドイツにおける重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • ドイツにおける閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数
  • フランスにおける閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • フランスにおける重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • フランスにおける閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数
  • イタリアにおける閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • イタリアにおける重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • イタリアにおける閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数
  • スペインにおける閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • スペインにおける重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • スペインにおける閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数
  • 英国における閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • 英国における重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • 英国における閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数
  • 日本における閉塞性睡眠時無呼吸症候群 (OSA) の発症件数
  • 日本における重症度別の閉塞性睡眠時無呼吸症候群 (OSA) の症例数
  • 日本における閉塞性睡眠時無呼吸症候群 (OSA) の診断・治療症例数

閉塞性睡眠時無呼吸症候群 (OSA) における現在のアンメットニーズ

現在の治療パラダイム

  • 閉塞性睡眠時無呼吸症候群 (OSA) の治療ガイドライン
  • 閉塞性睡眠時無呼吸症候群 (OSA) の現在の治療法

新興の治療薬

  • Dronabinol (RespireRx Pharmaceuticals)
  • BAY2586116 (Bayer)
  • AD109 (Apnimed)
  • AD036 (Apnimed)
  • AD128 (Apnimed)
  • THX-110 (Therapix bio)
  • AD182 and AD504 (Apnimed)
  • Lemborexant (Eisai)
  • MK-7264 (Merck)
  • Seltorexant (Janssen)
  • ACT-541468 (Idorsia)
  • SAS0421 (Apnimed)

OSA製品の位置付け

主要な競合企業

総合市場予測

主要サマリーの結果

  • G7の閉塞性睡眠時無呼吸症候群 (OSA) 総合市場
  • G7の閉塞性睡眠時無呼吸症候群 (OSA) 総合市場：治療別

市場予測：国別

  • 米国
    • 閉塞性睡眠時無呼吸症候群 (OSA) の米国市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) の米国市場：治療別
  • ドイツ
    • 閉塞性睡眠時無呼吸症候群 (OSA) のドイツ市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) のドイツ市場：治療別
  • フランス
    • 閉塞性睡眠時無呼吸症候群 (OSA) のフランス市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) のフランス市場：治療別
  • イタリア
    • 閉塞性睡眠時無呼吸症候群 (OSA) のイタリア市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) のイタリア市場：治療別
  • スペイン
    • 閉塞性睡眠時無呼吸症候群 (OSA) のスペイン市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) のスペイン市場：治療別
  • 英国
    • 閉塞性睡眠時無呼吸症候群 (OSA) の英国市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) の英国市場：治療別
  • 日本
    • 閉塞性睡眠時無呼吸症候群 (OSA) の日本市場
    • 閉塞性睡眠時無呼吸症候群 (OSA) の日本市場：治療別

市場の促進要因と障壁

付録

Mellalta Meetsについて

目次
Product Code: MM202023

Growth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. have mild OSA, while one out of 15 have moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2020 to 2030.

Obstructive sleep apnea (OSA)-also referred to as obstructive sleep apnea-hypopnea-is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep. These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.

Obstructive sleep apnea - OSA Epidemiology

OSA remains significantly under-recognized, as only 20% of cases in the United States according to the AASM and 20% of cases globally have been properly diagnosed. We hold our diagnosed and treatment cases estimates constant over the forecast period, and changes in the number of OSA cases are due to demographic shifts.

The reported rates of psychiatric diagnosis among modafinil users do seem to be higher than the 18.3% (of adults in the USA) stated in the 2016 National (USA) Survey on Drug Use and Mental Health. As per the survey, overall, modafinil was perceived by users as being safe. Modafinil users reported higher levels of illicit drug use and psychiatric diagnosis than would be expected from population-based data. More frequent reported modafinil use was associated with higher numbers of perceived benefits whilst reported frequency of use was not associated with the number of perceived risks, We are expecting 18% of the OSA patients on this therapy in the base year and will subsequently decline as the new therapies entering into the market.

Obstructive Sleep Apnea (OSA) Prevalence Mellalta Meets

Obstructive sleep apnea Market Forecast

The Obstructive Sleep Apnea (OSA) therapy market is expected to experience high growth throughout our study period, increasing from $XX million in 2017 to $XX billion in 2030, representing 17.78% annual growth. Primary drivers of this growth will be uptake of the therapies Modafinil/Armodafinil (Takeda), Solriamfetol/Sunosi (Jazz Pharmaceuticals), Dronabinol (RespireRx Pharmaceuticals), BAY2586116 (Bayer), AD109 (Apnimed), AD036 (Apnimed), AD128 (Apnimed) and THX-110 (Therapix bio), predominantly in the United States.

There are no specific treatments for the treatment Obstructive Sleep Apnea (OSA) and current care treatment for OSA involves CPAP (Continuous Positive Airway Pressure) is which is the leading device therapy for Obstructive Sleep Apnea (OSA). This treatment involves the patient wearing a mask that connects through a hose to a bedside air pump. Although the therapy has demonstrated improvements in patient-reported sleep quality and reductions in daytime sleepiness, around 35% - 65% are non-CPAP compliant. Patients complain of problems including mask discomfort, mask leakage, pressure intolerance, skin irritation, nasal congestion, nasal drying, nosebleeds, claustrophobia, and lack of intimacy. The CPAP therapy accounts for the 70% of the device-treated OSA population share.

Obstructive Sleep Apnea (OSA) Market Size by Country Mellalta Meets

Report Highlights:

  • Obstructive sleep apnea Current Market Trends
  • Obstructive sleep apnea Current & Forecasted Cases across the G7 Countries
  • Obstructive sleep apnea Market Opportunities And Sales Potential for Agents
  • Obstructive sleep apnea Patient-based Market Forecast to 2030
  • Obstructive sleep apnea Untapped Business Opportunities
  • Obstructive sleep apnea Product Positioning Vis-a-vis Competitors' Products
  • Obstructive sleep apnea KOLs Insight

Table of Contents

Obstructive Sleep Apnea Disease Background

  • Obstructive Sleep Apnea Definition
  • Symptoms
  • Risk Factor
  • Diagnosis

Epidemiology Estimated and Forecast to 2030

Epidemiology Research Method & Data Sources Used

  • Incident Cases of Obstructive Sleep Apnea in the United States 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in the United States 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in the United States 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Germany 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Germany 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Germany 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in France 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in France 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in France 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Italy 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Italy 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Italy 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Spain 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Spain 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Spain 2020-2030
  • Incident of Obstructive Sleep Apnea in the United Kingdom 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in the United Kingdom 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in the United Kingdom 2020-2030
  • Incident Cases of Obstructive Sleep Apnea in Japan 2020-2030
  • Cases of Obstructive Sleep Apnea by OSA by severity in Japan 2020-2030
  • Diagnosed & Treatment Cases of Obstructive Sleep Apnea in Japan 2020-2030

Current Unmet Needs in Obstructive Sleep Apnea

Current Treatment Paradigm

  • Treatment guidelines for Obstructive Sleep Apnea
  • Current Therapies for Obstructive Sleep Apnea

Emerging Therapies Chapters

  • Dronabinol (RespireRx Pharmaceuticals)
  • BAY2586116 (Bayer)
  • AD109 (Apnimed)
  • AD036 (Apnimed)
  • AD128 (Apnimed)
  • THX-110 (Therapix bio)
  • AD182 and AD504 (Apnimed)
  • Lemborexant (Eisai)
  • MK-7264 (Merck)
  • Seltorexant (Janssen)
  • ACT-541468 (Idorsia)
  • SAS0421 (Apnimed)

OSA Product Positioning

Key Competitors

Total Market Forecast

Key Summary Findings

  • G7 total Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
  • G7 total Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)

Market Forecast by Country

  • United States
    • United States Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • United States Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Germany
    • Germany Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Germany Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • France
    • France Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • France Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Italy
    • Italy Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Italy Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Spain
    • Spain Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Spain Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • United Kingdom
    • United Kingdom Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • United Kingdom Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)
  • Japan
    • Japan Market for Obstructive Sleep Apnea 2020-2030 (USD Million)
    • Japan Market for Obstructive Sleep Apnea by Therapies 2020-2030 (USD Million)

Market Drivers & Barriers

Appendix

About Mellalta Meets